Resources
Development of a Practical GMP-Compliant Manufacturing Process for T Cell-Derived Induced Pluripotent Stem Cells
GMP-compliant iPSC manufacturing has advanced significantly—yet producing clinical-grade cells still demands months of complex work. Published in Cytotherapy (2025), this study tackles that challenge directly.
The authors detail a complete workflow for reprogramming T cells from healthy donor peripheral blood into iPSC, yielding 13 unique lines suitable for clinical applications. The study focuses on standardizing cell enumeration, managing staff and materials efficiently, and reducing batch-to-batch variability. Gene deletions identified across the iPSC lines were independently verified using electronic genome mapping (EGM) on the OhmX™ Platform.
Share This
Cancer Research
Gain deeper insights and drive breakthroughs in cancer research with the OhmX™ Platform, powered by electronic genome mapping (EGM) and expertly engineered to unravel the complexities of structural variants (SVs) in cancer genomes.
Orthogonal Validation of NGS and LRS
Gain confidence in your genomic discoveries from NGS and long-read sequencing (LRS) platforms with a low-cost solution to verify, clarify, and identify structural variant (SV) calls.
Rare Disease
Unravel complexities and gain critical insights with the OhmX™ Platform, designed to help you push the boundaries of rare disease research.
Cell and Gene Therapy
EGM provides clarity to genomic integrity where other tools can’t.